文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

甲状腺癌患者接受131I治疗期间需透析的肾衰竭患者的管理

Management of Patients with Renal Failure Undergoing Dialysis During 131I Therapy for Thyroid Cancer.
PubMed 文献 · J Nucl Med · 2020-01-10

该研究总结了6例接受血液透析的终末期肾病甲状腺癌患者进行131I治疗的剂量学与毒性经验,两次透析分别在给药后42和90小时进行,全身放射性活度平均降低66.7%和53.3%,骨髓平均吸收剂量0.992 Gy,未观察到显著血液学毒性,作者认为约低于标称剂量30%的131I活度可平衡骨髓毒性与疗效。

要点

  • 6例血液透析的终末期肾病甲状腺癌患者接受131I治疗,透析在给药后42和90小时进行。
  • 首次透析后全身放射性活度平均降低66.7%,第二次后平均降低53.3%。
  • 骨髓平均估计总吸收剂量0.992 Gy,未观察到显著血液学毒性。

核心结论

  • 在血液透析的甲状腺癌患者中,131I活度约比标称剂量低30%似乎在无骨髓毒性与治疗疗效之间取得适当平衡。
  • 作者建议对转移性患者进行治疗前剂量学研究以计算应给予的活度,以避免过度照射。
  • 作者还建议在治疗剂量给药后进行的血液透析期间、在相同条件下进行剂量学监测。

研究设计与样本

  • 本研究为在代谢放疗单元对6例甲状腺刺激后接受血液透析的慢性肾衰竭甲状腺癌患者进行治疗的经验总结。
  • 在放射性药物给药后42和90小时进行两次血液透析。
  • 通过血样活度测量和住院期间定期全身测量(γ计数器)估计骨髓毒性,并对患者进行甲状腺和血液学监测以评估短期、中期和长期疗效与治疗毒性。

主要发现

  • 首次透析后全身放射性活度平均降低66.7%(范围60.1%-71.5%)。
  • 第二次透析后全身放射性活度平均降低53.3%(范围30.4%-67.8%)。
  • 所有患者骨髓平均估计总吸收剂量为0.992 Gy(范围0.431-2.323 Gy)。
  • 未观察到任何显著血液学毒性。
  • 临床、生物学和超声检查结果证实大多数患者消融治疗成功。

临床怎么用

  • 作者建议对转移性患者进行治疗前剂量学研究以计算应给予的活度,以避免过度照射。
  • 作者建议在治疗剂量给药后进行的血液透析期间、在相同条件下进行剂量学监测。
  • 作者认为约低于标称剂量30%的131I活度似乎在无骨髓毒性与治疗疗效之间取得适当平衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioactive iodine (131I) therapy may be used to treat thyroid cancer in end-stage renal disease patients who undergo hemodialysis. Because iodine uses predominantly renal clearance, treatment management in hemodialysis patients may be problematic, and no formal recommendations on hemodialysis currently exist. This work details our experience with treating thyroid cancer with iodine in chronic renal failure patients who require hemodialysis and details the dosimetry results obtained during treatment to ensure that the dose to the bone marrow (BM) was acceptable. Methods: We treated 6 patients in the metabolic radiotherapy unit after thyroid stimulation. Two hemodialysis sessions in the metabolic radiotherapy unit were performed at 42 and 90 h after radiopharmaceutical administration. BM toxicity was estimated with activity measurements from blood samples and with whole-body measurements that were regularly repeated during hospitalization and measured with a γ-counter. The patients underwent thyroid and hematologic monitoring to assess treatment efficacy and therapeutic toxicity in the short, medium, and long term. Results: Whole-body activity was reduced on average by 66.7% (range, 60.1%-71.5%) after the first dialysis session and by 53.3% (range, 30.4%-67.8%) after the second. The mean estimated total absorbed dose to the BM was 0.992 Gy for all patients (range, 0.431-2.323 Gy). We did not observe any significant hematologic toxicity, and the clinical, biologic, and ultrasound test results confirmed the success of ablative treatment for most patients. Conclusion: In hemodialysis patients with thyroid cancer, an 131I activity approximately 30% lower than the nominal dose appears to strike an appropriate balance between absence of BM toxicity and therapeutic efficacy. To avoid overirradiation, we recommend pretherapeutic dosimetry studies for metastatic patients to calculate the amount of activity to be administered. We also recommend dosimetry monitoring during the hemodialysis sessions performed after therapeutic dose administration and under the same conditions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vermandel M, Debruyne P, Beron A, et al. Management of Patients with Renal Failure Undergoing Dialysis During 131I Therapy for Thyroid Cancer. J Nucl Med. 2020. PMID: 31924716. doi:10.2967/jnumed.119.232017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。